2023-12-21 18:59:00 ET
A 10% lift to an analyst's stock price on Soleno Therapeutics (NASDAQ: SLNO) provided some nice lift to the biotech's shares on Thursday. They closed the day's trading session nearly 2.4% higher, more than double the percentage-rate increase of the S&P 500 index.
Well before market open that day, Guggenheim healthcare analyst Debjit Chattopadhyay upped his price target on Soleno to $44 per share from his previous $40. In doing so, he maintained his buy recommendation on the shares. The new level implies nearly 12% upside to the stock at its latest closing price.
Chattopadhyay's latest research note on the company wasn't publicly available, so we can't ascertain the factors behind his price-target raise.
For further details see:
Why Soleno Therapeutics Stock Ticked Higher on Thursday